These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 21208847)

  • 1. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
    Saif MW; Kaley K; Chu E; Copur MS
    Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
    Oncologist; 2012; 17(1):14. PubMed ID: 22210091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.
    Marino A; Caliolo C; Sponziello F; Nacci A; Quaranta A; Mazzoni E; Lutrino SE; Rizzo P; Calvani N; Orlando L; Schiavone P; Fedele P; D'Amico M; Chetrì MC; Cinefra M; Ferrara P; Cinieri S
    Tumori; 2015; 101(5):524-8. PubMed ID: 26045117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
    Saif MW; Peccerillo J; Potter V
    Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
    Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
    Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports.
    Langerak A; River G; Mitchell E; Cheema P; Shing M
    Clin Colorectal Cancer; 2009 Jan; 8(1):49-54. PubMed ID: 19203897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
    Heun J; Holen K
    Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience.
    van Hellemond IE; Creemers GJ; van Warmerdam LJ; de Jong FA; Koornstra RH
    Clin Oncol (R Coll Radiol); 2014 Mar; 26(3):135-41. PubMed ID: 24246276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
    Carneiro BA; Ramanathan RK; Fakih MG; Krishnamurthi SS; Lembersky BC; Stoller RG; Lancaster SL; Pinkerton RA; Crandall TL; Schmotzer AR; Potter DM; Bahary N
    Clin Colorectal Cancer; 2012 Mar; 11(1):53-9. PubMed ID: 21813336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
    Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
    Seront E; Marot L; Coche E; Gala JL; Sempoux C; Humblet Y
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S11-4. PubMed ID: 20189054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
    Kiss I; Mlcochova J; Bortlicek Z; Poprach A; Drabek J; Vychytilova-Faltejskova P; Svoboda M; Buchler T; Batko S; Ryska A; Hajduch M; Slaby O
    Anticancer Res; 2016 Sep; 36(9):4955-9. PubMed ID: 27630355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
    Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
    J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.